ClinicalTrials.gg
RecruitingNCT07121335SABR-OMOPUpdated Nov 18, 2026

SMC Radiation Oncology SABR Cohort for Oligometastasis

An observational study in Stereotactic Body Radiation Therapy (SBRT), Oligometastasis and Oligoprogression, sponsored by Samsung Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Samsung Medical Center · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to evaluate the efficacy and safety of stereotactic body radiotherapy (SABR) in patients with oligometastatic or oligoprogressive cancer.

The main questions it aims to answer are:

  1. oncologic outcomes (progression-free survival, local failure rate),
  2. patient-reported outcomes,
  3. physician-assessed toxicity, and
  4. dynamics of circulating tumor DNA (ctDNA) for biomarker analysis.
02

Conditions studied

  • Stereotactic Body Radiation Therapy (SBRT)
  • Oligometastasis
  • Oligoprogression
  • ctDNA
  • Patient-Reported Outcomes (PRO)

Keywords

  • Stereotactic body radiotherapy
  • Oligometastasis
  • Oligoprogression
  • ctDNA
03

In context

Lead sponsor

Samsung Medical Center is the lead sponsor of 1,013 studies on the registry; 153 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cancer patients who are Confirmed to have oligometastatic/oligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Performance status ( PS) 0-2
  • Diagnosed with disease
  • Confirmed to have oligometastatic/oligoprogressive cancer on imaging performed within 4 weeks (up to 5 lesions)

Exclusion criteria

Exclusion Criteria:

  • Patient with a history of prior radiotherapy to the site planned for SABR
  • Patients with concomitant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Interventions

  • RadiationStereotactic body radiotherapy (SBRT)

    Stereotactic body radiotherapy (SABR) using photon or proton beams will be delivered per standard practice (1-5 fractions).

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    Time from the start of stereotactic body radiotherapy (SABR) to the first documented event of local failure, distant failure, death from any cause, or last follow-up, whichever occurs first.

    Time frame: From start of SABR to the earliest of local failure, distant failure, death, or last follow-up. It will be measured at 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.

  2. Physician assessed toxicity

    Evaluated by treating physician based on CTCAE ver 5.0

    Time frame: 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.

  3. Patient-reported outcome

    It will be measured by PRO-CTCAE coreset 12.

    Time frame: 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.

  4. Local failure

    Local regrowth or progression at the site of SABR.

    Time frame: 1 month after completion of SABR, and at 6 months, 1 year, 2 years, and 3 years after SABR.

  5. Dynamics of ctDNA

    ctDNA analysis

    Time frame: It will be collected 1-week before SABR and 4-6 weeks after SABR.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 13, 2025
StartActual
May 1, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Mar 31, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07121335
Responsible party
Nalee Kim (Assistant professor, Samsung Medical Center) — Principal investigator
First posted
Aug 13, 2025
Start date
May 1, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Nalee Kim, MD, PhD
Contact
nalee.kim@samsung.com
82-2-3410-2612

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion